The OrbiMed-managed healthcare trust, which beat its benchmark in its last financial year with AstraZeneca as the top contributor, continues to buy back shares as it heads towards half-year results in November.

Worldwide Healthcare Trust (LSE:WWH), one of the largest specialist healthcare Investment trusts on the London market, is entering the final months of 2026 with a focus on Capital management and communication with shareholders. While there have been no major results announcements since the summer, a steady stream of share Buybacks and an investor update from its lead portfolio manager have kept the trust in view.

Annual results and AstraZeneca's contribution

The trust's most recent full-year results, covering the 12 months to 31 March 2026, were published in early June. The trust reported that it had beat its benchmark over the year, with AstraZeneca identified as the top contributor to portfolio performance. The Anglo-Swedish drugmaker has been a significant beneficiary of investor enthusiasm for its oncology pipeline and its long-term Revenue targets.

Alongside the results, the board declared a final Dividend on 3 June. Income is a secondary consideration for the trust, whose stated objective is to achieve a high level of capital growth through investment in the global healthcare sector, and the indicative Yield is modest at around 0.6%.

Buybacks and discount management

At a general meeting held on 2 June, shareholders approved the renewal of the trust's share buyback authority. The board has made regular use of that power, with transactions in own shares reported as recently as 30 September. Buybacks are a common tool among investment trusts trading at a discount to net asset value, as repurchasing shares below NAV enhances returns for remaining shareholders and can help support the share price.

Net Assets stood at approximately £1.44 billion at the end of July 2026. The five-year share price total return, at around 5.0%, highlights how difficult the past few years have been for healthcare investors, particularly those with exposure to smaller biotechnology companies, which have been out of favour for an extended period. It also helps to explain why the board has placed such emphasis on buybacks as a means of supporting the shares.

Manager update

OrbiMed, described as the world's largest dedicated healthcare investment firm, manages the portfolio. The trust has disclosed changes to the lead Portfolio Management arrangements at OrbiMed, and on 30 September lead portfolio manager Trevor Polischuk hosted an investor webinar discussing recent performance and how the portfolio is positioned for the remainder of 2026 and beyond.

Sector drivers and next steps

The outlook for the trust is closely tied to several sector-specific factors. These include US drug pricing policy and its implications for pharmaceutical margins, the pace of Merger and Acquisition activity among large drugmakers seeking to replenish pipelines, Federal Reserve Interest Rate decisions, which have a major influence on biotechnology valuations, and regulatory approval timelines at the US Food and Drug Administration.

The next major scheduled event is the half-year report for the six months to 30 September 2026, which last year was published in mid-November. Investors will be watching for updates on performance relative to the benchmark, the level of the discount and the scale of buyback activity. With recent news flow limited mainly to routine announcements, these results are likely to be the next significant catalyst.